Please login to the form below

Not currently logged in
Email:
Password:

OxyContin

This page shows the latest OxyContin news and features for those working in and with pharma, biotech and healthcare.

FDA awards another non-opioid pain drug breakthrough status

FDA awards another non-opioid pain drug breakthrough status

Meanwhile one company, Purdue Pharma, has become increasingly identified for fuelling the epidemic with its opioid products, especially OxyContin, a timed-release formulation of opioid pain medication oxycodone.

Latest news

  • Endo faces industry-first FDA call to pull its opioid painkiller Endo faces industry-first FDA call to pull its opioid painkiller

    Previously Purdue Pharma’s opioid painkiller Oxycontin was removed from the market when an abuse-resistant form became available, but the privately-held pharmaceutical company removed the drug from the market

  • Purdue gets FDA nod for abuse-deterrent painkiller Purdue gets FDA nod for abuse-deterrent painkiller

    Purdue already sells an abuse-deterrent product version of its OxyContin (oxycodone) product, and earlier this year got approval in the US for another around-the-clock opioid painkiller, Targiniq ER,

  • FDA approves pain drug that has reduced risk of abuse FDA approves pain drug that has reduced risk of abuse

    The pain relieving effects in Targiniq ER come from oxycodone – the active ingredient in Purdue's existing OxyContin - although the new product also contain naloxone, which reverses the effects of opioid ... The availability of the abuse-deterrent

  • A will of iron A will of iron

    In Brett O’Connor and Matthew Macland’s view, campaigns are all too often about a gentle putt. Find out why they believe two campaigns fell short

  • FDA bars generic version of Purdue’s painkiller OxyContin FDA bars generic version of Purdue’s painkiller OxyContin

    US regulators have banned generic versions of Purdue Pharma's painkiller OxyContin after the company received approval for updated labelling for a reformulated version of the drug that prevents abuse. ... Since its initial approval from the FDA in 1995,

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    11. Buvidal – an advance in opioid dependence treatment. Opioid addiction has surged in the US since the 1990s, when prescription drugs such as OxyContin and Vicodin became a common remedy for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • "Legal highs" ruling leaves illegal labs laughing

    Our agency was responsible for the EU launch of OxyContin and the first sublingual formulation of fentanyl, a powerful opioid that is abused by many drug addicts. ... So we are acutely aware of the devastation caused by the opioid epidemic in the US, and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics